<DOC>
	<DOCNO>NCT01579630</DOCNO>
	<brief_summary>The study aim randomize 52 patient advanced ( Stage IV ) EGFR mutation negative nonsquamous non-small cell lung cancer ( NSCLC ) respond ( CR/PR/SD ) 4 cycle pemetrexed / cisplatin pemetrexed/carboplatin first-line therapy . In order achieve , approximately 144 treatment naïve patient advance nonsquamous NSCLC need enrol around 6 investigational site Taiwan expertise lung cancer diagnosis .</brief_summary>
	<brief_title>Genius Study Study Compare Efficacy Safety Gefitinib/ Pemetrexed With Pemetrexed Alone Maintenance Therapy Patients With Stage IV EGFR Mutation Negative T790M Single Mutation Who Respond Pemetrexed/ Platinum First-line Therapy</brief_title>
	<detailed_description>The hypothesis test study gefitinib / pemetrexed maintenance therapy patient advance ( stage IV ) EGFR mutation negative nonsquamous NSCLC respond 4 cycle pemetrexed / cisplatin pemetrexed/carboplatin first-line therapy achieve longer PFS pemetrexed alone . We assume median PFS 4 month patient receive pemetrexed alone hazard ratio pemetrexed alone compare gefitinib/pemetrexed would 0.42 . It also indicate median PFS gefitinib/pemetrexed group approximately 9.52 month . This 2-arm study 1:1 randomisation . Assuming uniform accrual 12-month addition 12-month follow-up period , total evaluable number patient 52 achieve power 80 % one-sided significance level 0.025 detect difference gefitinib/pemetrexed pemetrexed alone . Assuming 60 % patient respond ( CR/PR/SD ) 4 cycle pemetrexed/gefitinib , among 60 % EGFR mutation negative , 144 patient need enrol receive 4 cycle pemetrexed/cisplatin pemetrexed/carboplatin first-line therapy . Besides , result anaplastic lymphoma kinase gene ( ALK ) mutation retrospectively collect mutation available study patient study period .</detailed_description>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion Criteria summary 1 . Provision write informed consent 2 . Patients age 20 year old 3 . Histological cytological confirm advanced ( stageIV ) nonsquamous NSCLC 4 . NSCLC treatment naïve ( except patient pre postoperative nonplatinum base adjuvant chemotherapy great 6 month prior enrolment enrol . ) 5 . Measurable disease accord RECIST ( Version 1.1 ) criterion 6 . World Health Organization ( WHO ) performance status ( PS ) 0 1 7 . Provision cancer tissue sample mutation test result EGFR mutation test negative ( single T790M mutation positive patient also enrol ) Exclusion Criteria summary 1 . Newly diagnosed Central Nervous System ( CNS ) metastases yet definitively treat surgery and/or radiation . 2 . Known severe hypersensitivity gefitinib , pemetrexed , cisplatin carboplatin excipients product 3 . Known severe hypersensitivity premedications require treatment pemetrexed / cisplatin pemetrexed/carboplatin doublet chemotherapy 4 . Absolute neutrophil count ( ANC ) less 2.0 x 109/L ( 2,000/mm3 ) , platelets less 100 x 109/L ( 100,000/mm3 ) haemoglobin le 10 g/dl 5 . Preexisting idiopathic pulmonary fibrosis evidence CT scan baseline 6 . Serum bilirubin great 1.5 time upper limit reference range 7 . Serum creatinine great 1.5 time ULRR 8 . Unable tolerate pemetrexed/ cisplatin pemetrexed/carboplatin doublet chemotherapy , judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Nonsquamous</keyword>
	<keyword>Maintenance therapy</keyword>
</DOC>